Last checked at 31 Aug 2016 11:37
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Scancell Holdings Share News (SCLP)
SCLP Share
Price
SCLP Share
News
SCLP Share
Chat11
SCLP Share
Trades
SCLP
Live RNS1
SCLP Share
Charts
SCLP Level 2
Console
SCLP Live
Share Price
SCLP Broker
Ratings
SCLP Directors
Deals
SCLP Financial
Diary
SCLP
Fundamentals
SCLP Short
Positions
SCLP
Media
Scancell Holdings Information
Share Price Information for Scancell Holdings (SCLP)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
9.75
Bid:
9.50
Ask:
10.00
Change:
0.00 (0.00%)
Spread:
0.50 (5.263%)
Open:
9.75
High:
9.75
Low:
9.75
Prev. Close:
9.75
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Scancell loses out on Cancer Research UK grant
Wed, 23rd Jan 2019 11:20
(Sharecast News) - Immunotherapies developer Scancell has seen Cancer Research UK pass on its submission into the Grand Challenge research initiative.Scancell's Project Blueprint, a proposal to eradicate established tumours with unique cancer vaccines, was shortlisted for the £60m grant but lost out to the likes of Brigham and Women's Hospital, Harvard Medical School, the Dana-Farber Cancer Institute, Harvard University and the University of California.The AIM-listed firm's proposal - which was submitted alongside BioNTech, Genentech and ISA Pharmaceuticals - was aimed at investigating the potential of cancer vaccines based on treatment with Modi-3 - a Scancell product developed from its Moditope platform.Chief scientific officer Lindy Durrant said: "We would like to congratulate the winners of Cancer Research UK's Grand Challenge, and to thank Cancer Research UK for putting the challenge forward to some of the best researchers in the world.""The shortlisting of our proposal represents a significant scientific endorsement of Scancell's technology and the team remains committed to meeting the challenges of improving cancer vaccines for all patients."As of 1200 GMT, Scancell shares had tumbled 15.03% to 8.12p.
More News
20 Jul 2016 12:35
Scancell granted product licence extension from Ichor Medical Systems
(ShareCast News) - Scancell, the developer of immunotherapies for cancer treatments, was granted a product licence option extension from Ichor Medical Systems. The extension is to licence the commercial use of Ichor's TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine,
Read more17 Jun 2016 12:24
Scancell suspends dosing with current supplies of SCIB1 for melanoma
(ShareCast News) - Shares in drug developer Scancell Holdings plunged almost 17% after it suspending dosing with current clinical trial supplies of SCIB1 for melanoma with immediate effect. Patients would be notified as soon as possible. AIM-quoted Scancell said quality-control analysis showed the
Read more17 Jun 2016 08:10
UPDATE 1-Scancell slumps as drug problem disrupts melanoma trial
(Adds latest shares, details) LONDON, June 17 (Reuters) - British drug developer Scancell has suspended dosing in a cancer clinical trial because of quality problems with an immunotherapy treatment, wiping more than a quarter off the value of its shares on Friday. The company said te
Read more17 Jun 2016 07:46
BUZZ-Scancell: drug problem spurs worst day in 3 yrs
** Drug developer Scancell's shares down 27 pct, worst day in nearly three years, after suspends dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1 ** Co says current supplies of drug no longer meet original specification and are no longer s
Read more17 Jun 2016 06:51
Drug problem forces Scancell to suspend cancer trial dosing
LONDON, June 17 (Reuters) - British drug developer Scancell said on Friday it was suspending dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1. The company said tests showed the product, which is being assessed for melanoma, was "no longer
Read more